logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
10/7/2020 6:50:00 AM Pfizer, Sangamo Dose First Participant In Phase 3 AFFINE Study Of Giroctocogene Fitelparvovec For Hemophilia A Patients
9/11/2020 8:35:00 AM Sangamo Therapeutics Appoints Kenneth Hillan To Board
6/24/2020 8:05:30 AM Sangamo Therapeutics Announces Changes To Its Research And Development Organization
6/18/2020 9:04:10 AM Pfizer, Sangamo Therapeutics Announce Updated Follow-up Data From Phase 1/2 Alta Study Of Giroctocogene Fitelparvovec
4/17/2020 8:36:44 AM Sangamo Therapeutics Appoints Mark McClung As EVP And Chief Business Officer
4/9/2020 8:05:06 AM Sangamo Therapeutics Announces Closing Of Previously Announced Sale Of Stock To Biogen
2/28/2020 7:11:21 AM Sangamo Therapeutics Q4 EPS $0.04 Vs Loss $0.18 Last Year
2/27/2020 4:11:32 PM Biogen And Sangamo Therapeutics Execute Global Licensing collaboration Agreement
2/12/2020 8:39:34 AM Sangamo Therapeutics Appoints John Markels To Board
12/9/2019 6:51:13 AM Sangamo Announces Preliminary Results From First 3 Patients In Phase 1/2 THALES Study
11/19/2019 7:07:56 AM Sangamo Therapeutics Reports UK Authorization Of Phase 1/2 Clinical Trial Evaluating CAR-Treg Cell Therapy TX200
11/1/2019 8:11:42 AM Sangamo Therapeutics Appoints Sung Lee As EVP And CFO